ACRO Biomedical Co Stock

ACRO Biomedical Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of ACRO Biomedical Co (6748.TWO) as of Jul 29, 2026 is -49.99. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -69.82 — a change of -28.40% (higher).

EV/EBIT

-49.99

YoY

-28.40%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of ACRO Biomedical Co is 2026 -49.99 . EV/EBIT (Enterprise Value to EBIT) of ACRO Biomedical Co was 2025 -69.82 . It decreases by -28.40% higher compared to the previous year.

The ACRO Biomedical Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
0.00 base
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
-18.84 base
Jan 1, 2022
-16.40 base
Jan 1, 2023
-46.92 base
Jan 1, 2024
-23.38 base
Jan 1, 2025
-42.97 base
YEARPRICE-TO-EBIT
2025 -42.97
2024 -23.38
2023 -46.92
2022 -16.40
2021 -18.84
2020 -
2019 -
2018 -
Access this data via the Eulerpool API
Get Free API Key

ACRO Biomedical Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides ACRO Biomedical Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates ACRO Biomedical Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots ACRO Biomedical Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if ACRO Biomedical Co grows earnings faster than its peers.

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ACRO Biomedical Co stock

EV/EBIT (Enterprise Value to EBIT) of ACRO Biomedical Co is -49.99 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — ACRO Biomedical Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — ACRO Biomedical Co